Login to Your Account

Review of 2012

Great Year on Capital Markets But Fundraising is a Challenge

By Peter Winter

Monday, January 7, 2013

Last year the prevailing global economic woes did not prove to be much of an impediment for biopharmaceutical companies in their quest to generate capital with a total of $24.8 billion raised. However, the ongoing financial uncertainties in Europe coupled with a weak domestic economy, a U.S. presidential election and a long contentious debate over the "fiscal cliff" all contributed toward making it a challenging environment for companies looking for funding.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription